Qualigen Therapeutics Inc (QLGN NASDAQ) stock market data APIs
$3.1113
-0.02(-0.6%)
as of March 20, 2025
Qualigen Therapeutics Inc Financial Data Overview
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Prev. Close
3.1363
Open
3.1113
High
3.1363
Low
3.077
52 wk Range
2.96-29.435
Market Cap
2 298 K
P/E Ratio
0.0009
Shares Outstanding
736 K
Revenue
4 984 K
EPS
-4.6964
Beta
0.109
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Qualigen Therapeutics Inc data using free add-ons & libraries
Get Qualigen Therapeutics Inc Fundamental Data
Qualigen Therapeutics Inc Fundamental data includes:
- Net Revenue: 4 984 K
- EBITDA: -6 886 340
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Qualigen Therapeutics Inc News
New
Lifecore Biomedical Announces Cooperation Agreement with 22NW
Lifecore Biomedical, Inc. Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board CHASKA, Minn., July 01, 2024 (GLOBE...
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumorsPhase 1a patient recruitment ongoing; company anticipates sha...
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers...
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
Poster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models CARLSBAD, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
